Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 21 | 2022 | 1033 | 4.020 |
Why?
|
| Exercise Therapy | 11 | 2019 | 64 | 3.060 |
Why?
|
| Quality of Life | 13 | 2022 | 459 | 2.980 |
Why?
|
| Exercise | 13 | 2023 | 524 | 2.810 |
Why?
|
| Survivors | 15 | 2022 | 126 | 2.780 |
Why?
|
| Fatigue | 8 | 2022 | 79 | 2.100 |
Why?
|
| Indians, North American | 5 | 2020 | 145 | 1.920 |
Why?
|
| Resistance Training | 5 | 2015 | 17 | 1.730 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 26 | 1.650 |
Why?
|
| Muscle Strength | 4 | 2015 | 26 | 1.360 |
Why?
|
| Breast Neoplasms | 7 | 2012 | 1426 | 1.070 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 336 | 1.060 |
Why?
|
| Middle Aged | 24 | 2022 | 9642 | 1.050 |
Why?
|
| Aged | 17 | 2022 | 6448 | 0.970 |
Why?
|
| Bone Density | 4 | 2012 | 76 | 0.890 |
Why?
|
| Humans | 47 | 2023 | 34853 | 0.880 |
Why?
|
| Health Promotion | 4 | 2023 | 588 | 0.870 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 756 | 0.860 |
Why?
|
| Athletic Injuries | 1 | 2021 | 29 | 0.790 |
Why?
|
| Sports | 1 | 2021 | 47 | 0.770 |
Why?
|
| Female | 26 | 2021 | 19873 | 0.740 |
Why?
|
| Community-Based Participatory Research | 3 | 2019 | 292 | 0.710 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 54 | 0.710 |
Why?
|
| Treatment Outcome | 10 | 2022 | 1349 | 0.680 |
Why?
|
| Patients | 1 | 2017 | 15 | 0.630 |
Why?
|
| Women's Health | 2 | 2015 | 135 | 0.610 |
Why?
|
| Caregivers | 1 | 2019 | 167 | 0.610 |
Why?
|
| Adult | 15 | 2022 | 11034 | 0.580 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 82 | 0.580 |
Why?
|
| Exercise Tolerance | 2 | 2019 | 16 | 0.570 |
Why?
|
| Confidentiality | 1 | 2016 | 26 | 0.570 |
Why?
|
| Information Dissemination | 1 | 2016 | 58 | 0.560 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2015 | 13 | 0.540 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 205 | 0.540 |
Why?
|
| Reproductive History | 1 | 2015 | 18 | 0.540 |
Why?
|
| Data Collection | 1 | 2016 | 188 | 0.530 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 44 | 0.530 |
Why?
|
| Male | 16 | 2021 | 18870 | 0.530 |
Why?
|
| Community-Institutional Relations | 2 | 2018 | 171 | 0.530 |
Why?
|
| Rest | 1 | 2015 | 25 | 0.520 |
Why?
|
| Physical Therapy Modalities | 1 | 2015 | 30 | 0.510 |
Why?
|
| Postmenopause | 2 | 2012 | 125 | 0.500 |
Why?
|
| Osteoporosis | 2 | 2012 | 32 | 0.500 |
Why?
|
| Depression | 2 | 2019 | 664 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 375 | 0.480 |
Why?
|
| Anxiety | 2 | 2019 | 705 | 0.470 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 531 | 0.470 |
Why?
|
| Risk Factors | 6 | 2021 | 3414 | 0.430 |
Why?
|
| Hip Fractures | 1 | 2012 | 26 | 0.420 |
Why?
|
| Hand Strength | 1 | 2011 | 21 | 0.420 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 21 | 0.400 |
Why?
|
| Practice Guidelines as Topic | 5 | 2012 | 187 | 0.390 |
Why?
|
| Motor Activity | 2 | 2012 | 393 | 0.360 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 2333 | 0.310 |
Why?
|
| Qualitative Research | 2 | 2020 | 393 | 0.300 |
Why?
|
| Young Adult | 3 | 2022 | 4012 | 0.300 |
Why?
|
| Arizona | 2 | 2018 | 92 | 0.300 |
Why?
|
| Physical Fitness | 2 | 2019 | 78 | 0.280 |
Why?
|
| Cohort Studies | 2 | 2020 | 1422 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2019 | 1353 | 0.250 |
Why?
|
| Michigan | 2 | 2023 | 22 | 0.240 |
Why?
|
| Life Style | 2 | 2020 | 288 | 0.240 |
Why?
|
| Marijuana Abuse | 1 | 2023 | 83 | 0.210 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 269 | 0.200 |
Why?
|
| Patient Compliance | 2 | 2015 | 202 | 0.200 |
Why?
|
| Activities of Daily Living | 2 | 2015 | 104 | 0.200 |
Why?
|
| Athletes | 1 | 2021 | 61 | 0.190 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 106 | 0.190 |
Why?
|
| Mental Health | 1 | 2004 | 270 | 0.190 |
Why?
|
| Housing | 1 | 2020 | 54 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2021 | 628 | 0.190 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 5 | 0.180 |
Why?
|
| Research Personnel | 2 | 2021 | 133 | 0.170 |
Why?
|
| Walking | 2 | 2021 | 64 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 33 | 0.170 |
Why?
|
| Employment | 1 | 2019 | 73 | 0.170 |
Why?
|
| Perception | 1 | 2020 | 183 | 0.170 |
Why?
|
| Pain | 1 | 2021 | 249 | 0.170 |
Why?
|
| Health Behavior | 1 | 2022 | 491 | 0.160 |
Why?
|
| Smoking | 2 | 2015 | 903 | 0.160 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 61 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2021 | 301 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 50 | 0.150 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 207 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 186 | 0.150 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 92 | 0.150 |
Why?
|
| Health Personnel | 1 | 2019 | 200 | 0.150 |
Why?
|
| Prognosis | 3 | 2019 | 707 | 0.150 |
Why?
|
| Privacy | 1 | 2016 | 7 | 0.140 |
Why?
|
| Bioethical Issues | 1 | 2016 | 5 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 608 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 330 | 0.140 |
Why?
|
| American Cancer Society | 2 | 2012 | 2 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 303 | 0.130 |
Why?
|
| Feedback | 1 | 2015 | 46 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2017 | 311 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 132 | 0.130 |
Why?
|
| Receptors, Nicotinic | 1 | 2015 | 91 | 0.120 |
Why?
|
| United States | 4 | 2021 | 3894 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 195 | 0.120 |
Why?
|
| Community Health Services | 1 | 2015 | 175 | 0.120 |
Why?
|
| Educational Status | 1 | 2014 | 295 | 0.110 |
Why?
|
| Mutation | 1 | 2017 | 1023 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 338 | 0.110 |
Why?
|
| Hip Joint | 1 | 2012 | 12 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2021 | 775 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2011 | 50 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 36 | 0.100 |
Why?
|
| Survival Rate | 2 | 2012 | 310 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 223 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2012 | 114 | 0.100 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 23 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 121 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 424 | 0.100 |
Why?
|
| Faculty | 2 | 2021 | 82 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2010 | 9 | 0.100 |
Why?
|
| Mentors | 2 | 2021 | 111 | 0.090 |
Why?
|
| Heart | 1 | 2012 | 178 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2012 | 196 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 841 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2009 | 7 | 0.090 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 73 | 0.090 |
Why?
|
| Methylphenidate | 1 | 2009 | 51 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2015 | 487 | 0.080 |
Why?
|
| Nursing Evaluation Research | 1 | 2008 | 12 | 0.080 |
Why?
|
| Body Composition | 1 | 2009 | 146 | 0.080 |
Why?
|
| Weight Gain | 1 | 2009 | 128 | 0.080 |
Why?
|
| Nurse's Role | 1 | 2008 | 31 | 0.080 |
Why?
|
| Valerates | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cachexia | 1 | 2008 | 7 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2009 | 167 | 0.080 |
Why?
|
| Glutamine | 1 | 2008 | 31 | 0.080 |
Why?
|
| Forecasting | 1 | 2008 | 124 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 62 | 0.080 |
Why?
|
| Methotrexate | 1 | 2007 | 20 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 165 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 143 | 0.080 |
Why?
|
| Aging | 1 | 2012 | 639 | 0.080 |
Why?
|
| Menopause | 1 | 2007 | 54 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2007 | 80 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2007 | 80 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 358 | 0.070 |
Why?
|
| Research Design | 1 | 2008 | 292 | 0.070 |
Why?
|
| Minority Groups | 2 | 2021 | 537 | 0.070 |
Why?
|
| Algorithms | 1 | 2009 | 435 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 628 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 178 | 0.070 |
Why?
|
| Age Factors | 1 | 2008 | 1007 | 0.070 |
Why?
|
| Health Status | 1 | 2008 | 356 | 0.070 |
Why?
|
| Physical Education and Training | 1 | 2023 | 22 | 0.060 |
Why?
|
| Memory, Short-Term | 1 | 2023 | 42 | 0.060 |
Why?
|
| Social Behavior | 1 | 2004 | 124 | 0.060 |
Why?
|
| School Health Services | 1 | 2023 | 77 | 0.050 |
Why?
|
| Environment Design | 1 | 2021 | 24 | 0.050 |
Why?
|
| Health Policy | 1 | 2023 | 149 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 229 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 2561 | 0.050 |
Why?
|
| Incidence | 2 | 2014 | 882 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2002 | 528 | 0.050 |
Why?
|
| Psychometrics | 1 | 2002 | 292 | 0.050 |
Why?
|
| Lymphedema | 1 | 2019 | 4 | 0.050 |
Why?
|
| Exercise Test | 1 | 2019 | 68 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 17 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 75 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 91 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 307 | 0.040 |
Why?
|
| Trust | 1 | 2018 | 119 | 0.040 |
Why?
|
| Decision Making | 1 | 2018 | 189 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 859 | 0.040 |
Why?
|
| Child | 1 | 2004 | 2875 | 0.030 |
Why?
|
| North America | 1 | 2014 | 60 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 88 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 74 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 316 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 5035 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2015 | 328 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 16 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 650 | 0.030 |
Why?
|
| Prescriptions | 1 | 2012 | 17 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 142 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2012 | 57 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2012 | 110 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1056 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1003 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1681 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2010 | 51 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 727 | 0.020 |
Why?
|
| Plethysmography | 1 | 2008 | 7 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 38 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 91 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 106 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 217 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 269 | 0.020 |
Why?
|